<?xml version="1.0" encoding="UTF-8"?>
<p>A retrospective data review for cognitive fusion-targeted biopsy performed at our institution during 2017 showed a clinically significant cancer detection rate of 52.8%,
 <xref rid="R18" ref-type="bibr">18</xref> while a literature from Germany revealed a clinically significant cancer detection rate of 45%
 <xref rid="R19" ref-type="bibr">19</xref> for software-based fusion-targeted biopsy. The patients with PI-RADS score â‰¥3 account for 60.6% in all patients who had undergone an mpMRI examination at our institution.
</p>
